METHODS: We searched for systematic reviews on breast cancer in The Cochrane Library from the date of inception to November 15, 2023, and identified guidelines that cited them. We described how systematic reviews were cited by the guidelines in each database and each year. Additionally, we presented the relationships between the conclusions of the systematic reviews and guideline recommendations and compared the consistency of the recommendations on the same topic across different guidelines.
RESULTS: A total of 64 systematic reviews and 228 guidelines were included in this study. The average number of the 64 systematic reviews cited by the guidelines was 5.91. We found that the guideline recommendations were irrelevant or inconsistent with the conclusions of the systematic reviews in 56 (38.36%) cited entries. We grouped recommendations on the same topic across different guidelines into one group, of which only 5 groups (15.15%) had completely consistent recommendations, and the other 28 groups (84.85%) had inconsistent recommendations.
CONCLUSIONS: The average number of citations for CSR on breast cancer in the guidelines was 5.91. There were also situations in which the guideline recommendations were inconsistent with the conclusions of the included systematic reviews, and recommendations on the same topic across different guidelines were inconsistent.
方法:我们在Cochrane图书馆中搜索了从成立之日起至2023年11月15日关于乳腺癌的系统综述,并确定了引用它们的指南。我们描述了每个数据库和每年指南如何引用系统综述。此外,我们介绍了系统综述的结论与指南建议之间的关系,并比较了不同指南中关于同一主题的建议的一致性。
结果:本研究共纳入64篇系统综述和228篇指南。指南引用的64篇系统综述的平均数为5.91篇。我们发现,在56个(38.36%)引用的条目中,指南建议与系统综述的结论无关或不一致。我们将不同指南中关于同一主题的建议分为一组,其中只有5组(15.15%)有完全一致的建议,其他28组(84.85%)的建议不一致。
结论:指南中关于乳腺癌的CSR的平均引用次数为5.91。也有准则建议与列入的系统审查的结论不一致的情况,不同指南中关于同一主题的建议不一致。